The Supreme Court on Monday extended temporary access to the abortion pill mifepristone through telehealth visits while justices weigh an emergency appeal challenging federal regulatory authority over drug safety standards. Justice Samuel Alito issued a temporary order last week maintaining widespread access to the drug, and the new order extends that stay until Thursday at 5 p.m. ET.
The order keeps on hold a May 1 decision from the 5th U.S. Circuit Court of Appeals that had required women to obtain the drug through in-person visits. The case represents the most significant abortion-related dispute to reach the high court in the fourth year since Roe v. Wade was overturned, when the court returned abortion policy to state legislatures.
State Authority vs. Federal Regulation
Louisiana sued the Food and Drug Administration last year over its policy allowing telehealth access to the pill, asserting in part that the Biden-era regulation undermined its abortion ban. A federal district court in April partly sided with the state, finding that the FDA's policy was arbitrary and capricious because the agency did not have adequate data to judge the drug's safety, but the district court held its own decision to give FDA time to complete a review of the drug.
A 5th Circuit panel of three judges, all appointed by Republican presidents, put the FDA's rule about mifepristone on hold earlier this month, meaning patients seeking to access the drug over the weekend were suddenly required to do so with in-person visits. Medical providers described the hours following that order as some of the craziest and most chaotic they've experienced.
Industry and Legal Response
Danco Laboratories, the maker of mifepristone, filed an emergency appeal on May 2, warning of the chaos. GenBioPro, which makes a generic version of the drug, filed its own appeal asserting that the 5th Circuit's ruling risked cutting off access for patients nationwide. The drug is most often used for abortion in combination with misoprostol. Medication abortions accounted for nearly two-thirds of all abortions in the U.S. in 2023, the last year for which statistics are available.
The current dispute is similar to one that reached the court three years ago. Lower courts then also sought to restrict access to mifepristone in a case brought by physicians who oppose abortion. The Supreme Court blocked the 5th Circuit ruling from taking effect over the dissenting votes of Alito and Justice Clarence Thomas. Then, in 2024, the high court unanimously dismissed the doctors' suit, reasoning they did not have the legal right, or standing, to sue.
Regulatory Standards Under Scrutiny
In the current dispute, mainstream medical groups, the pharmaceutical industry and Democratic members of Congress have weighed in cautioning the court against limiting access to the drug. Pharmaceutical companies said a ruling for abortion opponents would upend the drug approval process. The FDA has eased a number of restrictions initially placed on the drug, including who can prescribe it, how it is dispensed and what kinds of safety complications must be reported.
Despite those determinations, abortion opponents have been challenging the safety of mifepristone for more than 25 years. They have filed a series of petitions and lawsuits against the agency, generally alleging that it violated federal law by overlooking safety issues with the pill.
President Donald Trump's administration has been unusually quiet at the Supreme Court. It declined to file a written brief recommending what the court should do, even though federal regulations are at issue. The case puts Trump's Republican administration in a difficult place. Trump has relied on the political support of anti-abortion groups but has also seen ballot question and poll results that show Americans generally support abortion rights. Both sides took the silence as an implicit endorsement of the appellate ruling.
Alito is both the justice in charge of handling emergency appeals from Louisiana and the author of the 2022 decision that declared abortion is not a constitutional right and returned the issue to the states.
Why This Matters:
The case tests fundamental questions about federal regulatory authority, state sovereignty, and the drug approval process that extend beyond abortion policy. The pharmaceutical industry has warned that allowing courts to second-guess FDA safety determinations could destabilize the entire drug approval framework, potentially affecting investor confidence and innovation incentives. The dispute also highlights tensions between state police powers and federal administrative authority, with Louisiana asserting that federal telehealth regulations undermine democratically enacted state laws. The Trump administration's silence reflects the political complexity of balancing conservative constituencies while avoiding potential economic disruption to established regulatory processes. The outcome could set precedents affecting how states and federal agencies resolve conflicts over health policy, with implications for federalism and the scope of administrative discretion across multiple regulatory domains.